Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Davita Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Davita Inc (DVA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2026
Competitors
8
Named by the company
Peer Group Market Share
9.80 %
vs 9.70 % a year ago
Revenue Growth Y/Y
4.62 %
Peers: 3.50 %
Net Margin
6.23 %
Peers: 9.63 %

Key Findings: Davita Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 14,168M vs 130,687M combined for its competitors (9.8% combined share).
  • Trending: Latest-quarter revenue run-rate is holding steady (+1.0% annualized vs trailing 12 months), vs holding steady (+0.8%) for its tracked peer group.
  • Growth: Davita Inc generated 4.6% revenue growth year over year in Q3 2026, vs 3.5% for its competitors combined.
  • Profitability: Its 6.2% net margin compares with 9.6% for the peer group.
  • Scale: Davita Inc ranks #5 of 51 companies by market capitalization in the Healthcare Facilities industry, holding 4.5% of industry market cap.
  • Peer revenue share: Davita Inc accounted for 9.8% of combined revenue among its tracked peer group, up from 9.7% a year earlier.
  • Peer differentiation: Revenue per employee of $0.18M compares with $0.23M for the peer group (0.8x).
  • Structure: Davita Inc operates in the following segments: U. S. Dialysis And Related Lab Services, External Sources, Other with Intersegment, Other Operating, Intersubsegment Eliminations.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

DVA Sales vs. its Competitors, Q3 2026

Davita Inc reported revenue growth of 4.62 % year on year in Q3 2026, above its competitors' combined revenue growth of 3.50 %.

With a net margin of 6.23 %, Davita Inc reported lower profitability than its competitors (9.63 %).

Davita Inc generated 9.80 % of the combined sales of its peer group, up from 9.70 % a year earlier.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DVA/competitors
https://api.csimarket.com/api/v1/companies/DVA/relationships
https://api.csimarket.com/api/v1/companies/DVA/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

Davita Inc vs. its Competitors, Q3 2026

Revenue growth, year on year

Davita Inc +4.6 %
Competitors combined +3.5 %

Net income growth, year on year

Davita Inc -7.2 %
Competitors combined +2.8 %

Net margin

Davita Inc +6.2 %
Competitors combined +9.6 %

Revenue run-rate vs trailing 12 months

Davita Inc +1.0 %
Competitors combined +0.8 %

TTM net margin

Davita Inc +8.3 %
Competitors combined +10.1 %

TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Davita Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.

Competitor Financial Benchmarking - TTM Commercial

TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Davita Inc and its 4 competitor groupings. Available under Commercial License.

Entity TTM Revenue Latest Q ×4 Rev Run-rate vs TTM TTM Net Income TTM Net Margin
Davita Inc $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitors combined $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
High-Confidence Competitors (1) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Similar-Size Competitors (8) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Similar Growth & Profitability (6) $12,345M $12,345M +12.3% · Accelerating $1,234M 12.3%
Competitor Financial Benchmarking

TTM revenue, run-rate and net margin benchmarking across Davita Inc's competitor groups requires a Commercial License.

For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 4.6% for Davita Inc. Davita Inc's share of combined industry revenue moved from 3.28% to 2.99%, a loss of 0.29 percentage points.

Davita Inc's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity Profitable Expanding Above Industry Growth Distressed
Davita Inc Yes Yes Yes No
Competitors combined (20) 79% 75% 60% 0%
High-Confidence Competitors (3) 100% 100% 100% 33%
Similar-Size Competitors (9) 100% 100% 89% 0%
Similar Growth & Profitability (8) 100.00 % (8 of 8) 100.00 % (8 of 8) 75.00 % (6 of 8) 0.00 % (0 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q3 2026

9.8%market share
  • Davita Inc9.8%
  • Competitors combined90.2%

Share of combined quarterly revenue of Davita Inc and its 8 competitors.

See Davita Inc's full market share breakdown »

DVA Stock Performance relative to its Competitors

DVA Competitors (weighted) Percent change over the selected range

Davita Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
61.1%beat U.S.A. 500
Competitors Combined
(11 of 18)
33.3%beat U.S.A. 500
High-Confidence
(1 of 3)
55.6%beat U.S.A. 500
Similar-Size
(5 of 9)
71.4%beat U.S.A. 500
Similar Growth & Profitability
(5 of 7)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Davita Inc 57.20 % Outperformed
Competitors combined (18) 40.4% 63.2%
High-Confidence Competitors (3) 40.4% 63.2%
Similar-Size Competitors (9) 40.4% 63.2%
Similar Growth & Profitability (7) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Davita Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

DVA Stock Performance relative to High-Confidence Competitors

DVA High-Confidence Competitors (equal-weighted, 3) Percent change over the selected range

DVA Stock Performance relative to Similar-Size Competitors

DVA Similar-Size Competitors (equal-weighted, 9) Percent change over the selected range

DVA Stock Performance relative to Similar Growth & Profitability Competitors

DVA Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#CompetitorTTM Share Price Returnvs U.S.A. 500
1 Rockwell Medical inc 282.9% Outperformed
2 Acadia Healthcare Company Inc 282.9% Outperformed
3 National Healthcare Corp 282.9% Outperformed
4 Aveanna Healthcare Holdings Inc 282.9% Outperformed
5 Quest Diagnostics Inc 282.9% Outperformed
Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Davita Inc's best-performing competitors requires a Commercial License.

Source: CSIMarket API, trailing 12 months.

Davita Inc's Comment on Competition and Industry Peers

U.S. and International dialysis competition
The U.S. dialysis industry has consolidated significantly over time but still remains highly competitive, particularly in terms of acquiring existing outpatient dialysis centers. We continue to face a high degree of competition in the U.S. dialysis industry from large and medium-sized providers who compete directly with us for the acquisition of dialysis businesses, relationships with physicians to act as medical directors and for individual patients. In addition, as we continue our international dialysis expansion into various international markets, we will face competition from large and medium-sized providers for these acquisition targets as well. Because of the ease of entry into the dialysis business and the ability of physicians to be medical directors for their own centers, competition for growth in existing and expanding markets is not limited to large competitors with substantial financial resources. Acquisitions, developing new outpatient dialysis centers, patient retention and physician relationships are a critical component of our growth strategy and our business could be adversely affected if we are not able to continue to make acquisitions on reasonable terms, continue to develop new dialysis centers, maintain or establish new relationships with physicians or if we experience significant patient attrition to our competitors. Competition for qualified physicians to act as medical directors and for inpatient dialysis services agreements with hospitals is also intense. Occasionally, we have also experienced competition from former medical directors or referring physicians who have opened their own dialysis centers. In addition, we experience competitive pressures in connection with negotiating contracts with commercial healthcare payors.

The two largest dialysis companies, FMC and our company, account for approximately 71% of outpatient dialysis patients in the U.S. with our company serving approximately 35% of the total outpatient dialysis patients. Approximately 44% of the centers not owned by us or FMC are owned or controlled by hospitals or non-profit organizations. Hospital-based and non-profit dialysis units typically are more difficult to acquire than physician-owned centers.

HCP’s competition
HCP’s business is highly competitive. HCP competes with managed care organizations, hospitals, medical groups and individual physicians in its markets. HCP competes with other primary care physician groups or physicians who contract with health plans for membership. Health plans contract with care providers on the basis of costs, reputation, scope, efficiency and stability. Individual members select a primary care physician at the time of membership with the health plan. Location, name recognition, quality indicators and other factors go into that decision. For example, in California, HCP competes with both Permanente Medical Group, which is the exclusive provider for Kaiser, and Heritage Provider Network. However, HCP’s principal competitors for members and health plan contracts vary by market.
Corporate compliance program
Our businesses are subject to extensive federal, state and local government regulations. Management has designed and implemented a corporate compliance program as part of our commitment to comply fully with all applicable laws and regulations and to maintain the high standards of conduct we expect from all of our teammates. We continuously review this program and enhance it as necessary. The primary purposes of the program include:
Assessing and identifying risks for existing and new businesses, such as HCP;

Increasing, through training and education, the awareness of our teammates and affiliated professionals of the necessity of complying with all applicable laws, regulations and company policies and procedures;

Auditing and monitoring the activities of our operating units and business support functions on a regular basis to identify potential instances of noncompliance in a timely manner; and

Ensuring that we take steps to resolve instances of noncompliance or to address areas of potential noncompliance as promptly as we become aware of them.

We have a code of conduct that each of our teammates and affiliated professionals must follow and we have a confidential toll-free hotline for teammates and patients to report potential instances of noncompliance. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Operating Officer and to the Compliance Committee of our Board of Directors.

Publicly Traded Peers of Davita Inc

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Davita Inc 12,514.87 14,167.55 1,172.22 78,000
Hca Healthcare Inc 108,716.78 78,701.00 7,298.00 320,000
Quest Diagnostics Inc 28,789.04 11,841.00 1,166.00 57,000
Tenet Healthcare Corp 23,476.36 22,154.00 3,814.00 99,000
Encompass Health Corporation 13,752.90 6,338.10 808.60 42,000
Universal Health Services Inc 11,793.28 18,114.49 1,550.21 101,500
SUBTOTAL 228,895.43 213,938.30 17,160.55 948,873
15 more competitors available

Sign in to see all competitors of Davita Inc .

Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Davita Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Davita Inc's Competitors Named by the Company

Competitive relationships identified from Davita Inc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Nuwellis Inc Company report 85% 2022 to 2026 3
Unicycive Therapeutics Inc Company report 85% 2022 to 2026 3
Astrana Health Inc Company report 85% 2022 to 2026 3
Fresenius Medical Care Ag Company report 85% 2022 to 2026 3
Nephros Inc Company report 85% 2022 to 2026 3
Rockwell Medical inc Company report 85% 2022 to 2026 3
Hca Healthcare Inc Company report 85% 2022 to 2026 3
Tenet Healthcare Corp Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Davita Inc's named competitors require a Commercial License.

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Davita Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Davita Inc U. S. Dialysis And Related Lab Services 84.64 % External Sources 84.45 % Other with Intersegment 15.42 %
Hca Healthcare Inc American Group 34.50 % Atlantic Group 32.35 % National Group 28.91 %
Quest Diagnostics Inc Diagnostic Information Services Business 98.00 % Other Operating 2.00 % -
Tenet Healthcare Corp Hospital Operations 75.65 % Ambulatory Care 24.35 % -
Encompass Health Corporation Inpatient Rehabilitation 100.00 % - -
Universal Health Services Inc Acute Care Hospital Services 58.40 % Behavioral Health Services 41.54 % Corporate and Unallocated 0.06 %

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

9 more Peers available

Sign in to see all peers for Davita Inc .

Davita Inc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Davita Inc 12,515 181,635 15,028
Hca Healthcare Inc 108,717 245,941 22,806
Quest Diagnostics Inc 28,789 207,737 20,456
Tenet Healthcare Corp 23,476 223,778 38,525
Encompass Health Corporation 13,753 150,907 19,252
Universal Health Services Inc 11,793 178,468 15,273
PEERS TOTAL 216,381 229,391 18,359
15 more Peers available

Sign in to see all peers for Davita Inc .

Davita Inc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.
Company Largest Market 2nd Market 3rd Market
Rockwell Medical inc United States 86.19 % Non-US 16.41 % -

Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Davita Inc's Position in Industry Market Structure

Market-capitalization share and concentration across all 48 companies in Davita Inc's industry classification, broader than the peer set above. Market cap in millions of $.

Davita Inc ranks #5 of 48 companies by market capitalization in its industry, holding 4.54 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,836, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).

Rank Company Market Cap Industry Share
1 Hca Healthcare Inc 111,528 40.08 %
2 Tenet Healthcare Corp 24,456 8.79 %
3 Brightspring Health Services Inc 14,994 5.39 %
4 Encompass Health Corporation 13,794 4.96 %
5 Davita Inc 12,627 4.54 %
6 Universal Health Services Inc 1,234 5.2%
7 Ensign Group Inc 1,234 5.2%
8 Pacs Group Inc 1,234 5.2%
9 Chemed Corporation 1,234 5.2%
10 Fresenius Medical Care Ag 1,234 5.2%
Full Industry Market Structure

Market cap and industry share for the rest of Davita Inc's industry peers requires a Commercial License.

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.

Davita Inc's Same-Size Peers & Stock Performance

Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.
Rank Company Market Cap TTM Return 3M Momentum Beta Sharpe (1Y)
1 Hca Healthcare Inc 111,528 6.18 % 23.68 % 0.33 0.19
2 Tenet Healthcare Corp 24,456 42.65 % 8.72 % 0.84 0.72
3 Brightspring Health Services Inc 14,994 108.80 % 10.31 % 1.05 1.72
4 Encompass Health Corporation 13,794 19.88 % 11.61 % 0.37 0.61
5 Davita Inc 12,627 57.21 % 6.11 % 0.36 1.11
6 Universal Health Services Inc 1,234 12.3% 4.5% 1.10 0.80
7 Ensign Group Inc 1,234 12.3% 4.5% 1.10 0.80
8 Pacs Group Inc 1,234 12.3% 4.5% 1.10 0.80
9 Chemed Corporation 1,234 12.3% 4.5% 1.10 0.80
10 Fresenius Medical Care Ag 1,234 12.3% 4.5% 1.10 0.80
Full Same-Size Peer Performance

Market cap, return, momentum, beta and Sharpe ratio for the rest of Davita Inc's same-size peers requires a Commercial License.

Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.

Davita Inc's Profitability & Cost Structure

Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (113 companies). See the full Healthcare Facilities industry profitability benchmarks.
Metric Company Industry Difference
Gross Margin 0.00 % 34.25 % (avg) -34.2 pp
Operating Margin 14.97 % industry median +5.1 pp
EBITDA Margin 15.95 % 2.94 % (avg) +13.0 pp
Capital Intensity (Capex / Revenue) 4.07 % 3.80 % (avg) +0.3 pp

Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.

Davita Inc's Valuation vs Competitive Position

Valuation multiples vs the Healthcare Facilities industry average (113 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Healthcare Facilities industry valuation benchmarks.
Metric Company Industry Average Difference
P/E 16.6x 21.2x -4.6x
EV / EBITDA 12.6x 13.9x -1.3x
P/B -23.9x 3.1x -27.0x
Return on Equity - industry aggregate -
Return on Invested Capital 11.42 % 1.98 % (avg) 9.44 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Davita Inc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.
Metric 20182019202020212022202320242025
Revenue Growth -31.55 %-18.78 %1.42 %0.59 %-0.08 %4.57 %5.56 %6.46 %
Operating Margin 10.88 %14.43 %14.67 %15.47 %11.53 %13.20 %16.31 %14.98 %
Return on Invested Capital 7.97 %9.14 %9.65 %10.38 %8.26 %9.83 %13.18 %13.70 %
P/E 74.7x13.8x17.9x12.1x12.8x14.1x16.3x14.4x

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Davita Inc's Strategic Group Map

Davita Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.

Revenue Growth (TTM, %)Operating Margin (%)CONUHOSDavita IncAUNACHEUHSMDNHCPGNY

Davita Inc's trailing-12-month revenue growth of 6.4% and operating margin of 15.0% compares with an average of 8.3% growth and 12.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Davita Inc sits below that peer average on growth and above it on margin.

Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.

Davita Inc's BCG Growth-Share Matrix

See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.

Question Mark Star Dog Cash Cow Relative Market Share (vs largest competitor) Industry Revenue Growth (%) Davita Inc

Davita Inc falls in the Dog quadrant: relative market share of 0.11x vs its largest competitor, in an industry growing revenue 5.2% (median, trailing 12 months).

Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Hca Healthcare Inc alone holds 40% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.

Davita Inc's Competitive Forces (Porter's Five Forces)

Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.
Force Assessment Basis
Competitive Rivalry Moderate Industry HHI of 1,836 (see Industry Market Structure & Concentration above)
Barriers to Entry Moderate, in line with the industry Capital intensity (capex / revenue) of 4.07 % vs industry average 3.80 % (see Profitability & Cost Structure above)

Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Davita Inc's dedicated Suppliers and Customers pages, not here.

Davita Inc's Industry Attractiveness & Competitive Strength

See Methodology: GE/McKinsey Matrix for how the two axes are built.

High Strength
Medium Strength
Low Strength
High Attractiveness
Invest / Grow
Invest / Grow
Selective
Medium Attractiveness
Invest / Grow
Selective Davita Inc
Harvest
Low Attractiveness
Selective
Harvest
Harvest / Divest

Davita Inc falls in the Medium attractiveness / Medium strength cell: Selective.

Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.

Davita Inc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

  • Operating margin 5.1 points above the industry median.
  • Outperforming the U.S.A. 500 over the trailing 12 months.

Weaknesses

  • Low relative market share vs the industry leader (0.11x).

Opportunities

  • Trades at a lower P/E than the industry average (16.6x vs 21.2x) despite a higher return on invested capital -- a possible re-rating opportunity.

Threats

  • Industry dominated by Hca Healthcare Inc , holding 40.08 % of industry market cap.

Methodology: see Methodology: SWOT Analysis.

Davita Inc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Davita Inc 0.21 1.39 - 0.80
Hca Healthcare Inc 0.05 0.90 - 1.26
Quest Diagnostics Inc 0.28 1.35 0.74 0.71
Tenet Healthcare Corp 0.50 1.51 3.47 0.72
Encompass Health Corporation 0.10 1.14 1.16 0.86
Universal Health Services Inc 0.04 1.07 0.72 1.16
15 more Peers available

Sign in to see all peers for Davita Inc .

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Davita Inc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Davita Inc Q3 2026+4.6 %+0.7 %-7.2 %-35.0 %
Hca Healthcare Inc Q3 2026+3.6 %-1.9 %-17.0 %-7.1 %
Quest Diagnostics IncQ3 2026+10.0 %+1.8 %+20.5 %-6.6 %
Tenet Healthcare CorpQ3 2026+6.5 %+0.1 %+110.5 %+16.7 %
Encompass Health CorporationQ3 2026+8.9 %+0.8 %-14.1 %-27.7 %
Universal Health Services Inc Q2 2026+8.3 %+3.2 %+0.5 %+1.6 %
PEERS TOTAL+4.6 %+1.9 %+11.3 %+5.3 %
15 more Peers available

Sign in to see all peers for Davita Inc .

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Davita Inc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Davita Inc Q3 2026---4.0 %-6.1 %
Hca Healthcare Inc Q3 2026--+5.4 %+10.2 %
Quest Diagnostics IncQ3 2026+10.1 %+1.9 %+15.3 %+20.3 %
Tenet Healthcare CorpQ3 2026+25.7 %+8.4 %-29.3 %+17.9 %
Encompass Health CorporationQ3 2026--+25.3 %+6.4 %
Universal Health Services Inc Q2 2026---14.4 %+4.8 %
15 more Peers available

Sign in to see all peers for Davita Inc .

Davita Inc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Davita Inc 6.65%6.13%-5.75-
Hca Healthcare Inc 11.73%15.54%-6.85-
Quest Diagnostics Inc6.96%8.01%15.22%7.4336.62
Tenet Healthcare Corp12.39%10.91%57.13%8.541.88
Encompass Health Corporation10.99%10.41%24.08%9.41-
Universal Health Services Inc 9.92%12.43%20.89%6.75-
15 more Peers available

Sign in to see all peers for Davita Inc .

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Davita Inc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Davita Inc 15.790.880.84--
Hca Healthcare Inc 17.451.380.61--
Quest Diagnostics Inc25.892.431.0478.873.62
Tenet Healthcare Corp8.481.060.07-3.17
Encompass Health Corporation21.562.170.672,115.833.93
Universal Health Services Inc 8.060.650.13380.641.56
PEERS AVERAGE13.341.07147.625.11
15 more Peers available

Sign in to see all peers for Davita Inc .

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API Connect Your AI